MEI PHARMA INC (MEIP) Stock Price, Forecast & Analysis
USA - NASDAQ:MEIP - US55279B3015 - Common Stock
MEIP Key Statistics, Chart & Performance
The current stock price of MEIP is 3.07 USD. In the past month the price decreased by -35.91%. In the past year, price increased by 1.32%.
MEIP Latest News, Press Relases and Analysis
MEIP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.19 | 387.16B | ||
| AMGN | AMGEN INC | 14.64 | 172.38B | ||
| GILD | GILEAD SCIENCES INC | 14.51 | 147.46B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.59 | 104.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.61 | 69.69B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 868.04 | 58.03B | ||
| INSM | INSMED INC | N/A | 40.10B | ||
| NTRA | NATERA INC | N/A | 27.39B | ||
| BIIB | BIOGEN INC | 9.29 | 22.80B | ||
| INCY | INCYTE CORP | 16.51 | 20.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.01 | 20.30B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 36.45 | 15.11B |
Related stock screener links
About MEIP
Company Profile
MEI Pharma, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical compounds. The company is headquartered in San Diego, California and currently employs 28 full-time employees. The company went IPO on 2003-12-18. The firm's treasury initiative is anchored by Litecoin. The firm has discontinued the clinical development of voruciclib, while certain nonclinical activities related to its drug candidate assets continue to be conducted by it. As part of the review of strategic alternatives, the Company may consider options such as out-licensing opportunities for existing programs and merger and acquisition opportunities.
Company Info
MEI PHARMA INC
9920 Pacific Heights Blvd, Suite 150
San Diego CALIFORNIA 92130 US
CEO: Daniel P. Gold
Employees: 28
Phone: 18583697100
MEI PHARMA INC / MEIP FAQ
What does MEIP do?
MEI Pharma, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical compounds. The company is headquartered in San Diego, California and currently employs 28 full-time employees. The company went IPO on 2003-12-18. The firm's treasury initiative is anchored by Litecoin. The firm has discontinued the clinical development of voruciclib, while certain nonclinical activities related to its drug candidate assets continue to be conducted by it. As part of the review of strategic alternatives, the Company may consider options such as out-licensing opportunities for existing programs and merger and acquisition opportunities.
What is the stock price of MEI PHARMA INC today?
The current stock price of MEIP is 3.07 USD. The price increased by 10.43% in the last trading session.
Does MEIP stock pay dividends?
MEIP does not pay a dividend.
What is the ChartMill technical and fundamental rating of MEIP stock?
MEIP has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the GICS sector and industry of MEIP stock?
MEI PHARMA INC (MEIP) operates in the Health Care sector and the Biotechnology industry.
What is the market capitalization of MEIP stock?
MEI PHARMA INC (MEIP) has a market capitalization of 100.82M USD. This makes MEIP a Micro Cap stock.
Who owns MEI PHARMA INC?
You can find the ownership structure of MEI PHARMA INC (MEIP) on the Ownership tab.
MEIP Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to MEIP. When comparing the yearly performance of all stocks, MEIP is one of the better performing stocks in the market, outperforming 75.49% of all stocks.
MEIP Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to MEIP. While MEIP has a great health rating, there are worries on its profitability.
MEIP Financial Highlights
Over the last trailing twelve months MEIP reported a non-GAAP Earnings per Share(EPS) of 2.67. The EPS increased by 157.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -152.38% | ||
| ROE | -162.03% | ||
| Debt/Equity | 0 |
MEIP Forecast & Estimates
6 analysts have analysed MEIP and the average price target is 6.12 USD. This implies a price increase of 99.35% is expected in the next year compared to the current price of 3.07.
For the next year, analysts expect an EPS growth of -339.91% and a revenue growth -100% for MEIP